{
"ranked_hypotheses": [
{
"title": "cGAS-STING Pathway Hyperactivation Mediates Tau Propagation",
"description": "Pathological tau triggers cytosolic DNA release and mitochondrial DNA stress, activating cGAS-STING signaling in neurons and microglia. This creates a feedforward inflammatory loop that accelerates tau pathology spread and impairs neuronal proteostasis. Tier 1 translational feasibility with 5-8 year development timeline.",
"target_gene": "cGAS (CGAS), STING (TMEM173)",
"dimension_scores": {
"evidence_strength": 0.76,
"novelty": 0.70,
"feasibility": 0.82,
"therapeutic_potential": 0.75,
"mechanistic_plausibility": 0.72,
"druggability": 0.78,
"safety_profile": 0.65,
"competitive_landscape": 0.80,
"data_availability": 0.75,
"reproducibility": 0.78
},
"composite_score": 0.76,
"evidence_for": [
{"claim": "cGAS-STING activation detected in P301S tauopathy mice", "pmid": "32142648"},
{"claim": "Cytosolic mtDNA accumulation observed in neurodegeneration", "pmid": "29643778"},
{"claim": "STING inhibition reduces neuroinflammation and improves behavior in models", "pmid": "32817599"},
{"claim": "Type I interferon response genes upregulated in AD and Pick's disease brains", "pmid": "33277574"}
],
"evidence_against": [
{"claim": "STING inhibitors may impair peripheral antiviral immunity with chronic CNS dosing", "pmid": "N/A"},
{"claim": "Mouse CNS immune architecture differs from human; microglial density not fully conserved", "pmid": "N/A"}
]
},
{
"title": "TREM2-Dependent Microglial State Transition as Therapeutic Window in Alzheimer's Disease",
"description": "Heterozygous TREM2 loss-of-function variants impair transition of microglia from homeostatic to disease-associated (DAM) state, preventing effective phagocytosis of amyloid plaques. Enhancing TREM2 signaling may restore neuroprotective microglial functions. Tier 2 feasibility with moderate-high druggability via agonist antibodies.",
"target_gene": "TREM2, SYK signaling pathway",
"dimension_scores": {
"evidence_strength": 0.78,
"novelty": 0.65,
"feasibility": 0.68,
"therapeutic_potential": 0.72,
"mechanistic_plausibility": 0.61,
"druggability": 0.70,
"safety_profile": 0.60,
"competitive_landscape": 0.75,
"data_availability": 0.72,
"reproducibility": 0.68
},
"composite_score": 0.69,
"evidence_for": [
{"claim": "TREM2 R47H variant increases AD risk ~3-fold", "pmid": "23350616"},
{"claim": "Single-cell RNA-seq reveals impaired DAM formation in Trem2-deficient mice", "pmid": "28120864"},
{"claim": "Trem2 knockout mice show increased amyloid seeding", "pmid": "29431764"},
{"claim": "TREM2-agonist antibodies promote microglial amyloid uptake", "pmid": "33850021"}
],
"evidence_against": [
{"claim": "Human Nasu-Hakola disease (complete TREM2 deficiency) doesn't show classical amyloid-driven AD", "pmid": "N/A"},
{"claim": "DAM as cause vs consequence remains unresolved", "pmid": "N/A"},
{"claim": "Mixed human imaging data on amyloid burden in TREM2 variant carriers", "pmid": "32019990"},
{"claim": "TREM2 deficiency can be protective in EAE contexts", "pmid": "26385461"}
]
},
{
"title": "Astrocyte-Neuron Metabolic Coupling Failure Precedes Neurodegeneration in FTD-GRN",
"description": "Progranulin haploinsufficiency in FTD impairs astrocyte lactate production via MCT4, reducing neuronal glucose uptake and making neurons vulnerable to metabolic stress. Tier 2 feasibility with reasonable therapeutic entry points.",
"target_gene": "GRN, SLC16A3 (MCT4)",
"dimension_scores": {
"evidence_strength": 0.71,
"novelty": 0.72,
"feasibility": 0.66,
"therapeutic_potential": 0.68,
"mechanistic_plausibility": 0.70,
"druggability": 0.62,
"safety_profile": 0.68,
"competitive_landscape": 0.70,
"data_availability": 0.65,
"reproducibility": 0.72
},
"composite_score": 0.69,
"evidence_for": [
{"claim": "Grn-/- mice show astrocyte dysfunction and lysosomal abnormalities", "pmid": "21994255"},
{"claim": "Progranulin localizes to astrocytes, particularly around synapses", "pmid": "20819946"},
{"claim": "Astrocyte-neuron lactate shuttle critical for synaptic activity", "pmid": "24969124"},
{"claim": "MCT4 expression reduced in Grn knockout mice", "pmid": "33727733"}
],
"evidence_against": [
{"claim": "Metabolic coupling mechanisms may not be primary drivers, requiring validation of causal sequence", "pmid": "N/A"},
{"claim": "MCT4 targeting may affect peripheral lactate metabolism", "pmid": "N/A"}
]
},
{
"title": "Nuclear TDP-43 Depletion Drives Synaptic Splicing Dysregulation in ALS-FTD",
"description": "TDP-43 proteinopathy leads to progressive nuclear depletion, causing widespread alternative splicing defects at synapses. Despite highest original confidence (0.82), mechanistic critiques reveal causality gaps. ASO-based approach is Tier 3 with 10-12 year timeline.",
"target_gene": "TARDBP, splicing targets (Sortilin1, Synaptojanin1)",
"dimension_scores": {
"evidence_strength": 0.82,
"novelty": 0.55,
"feasibility": 0.52,
"therapeutic_potential": 0.58,
"mechanistic_plausibility": 0.58,
"druggability": 0.68,
"safety_profile": 0.55,
"competitive_landscape": 0.65,
"data_availability": 0.75,
"reproducibility": 0.62
},
"composite_score": 0.62,
"evidence_for": [
{"claim": "TDP-43 aggregates found in ~95% of ALS and ~50% of FTD cases", "pmid": "19270868"},
{"claim": "Nuclear TDP-43 loss precedes cytoplasmic aggregation in patient-derived neurons", "pmid": "28712719"},
{"claim": "Conditional TDP-43 knockdown in mice reproduces ALS phenotypes", "pmid": "22958898"}
],
"evidence_against": [
{"claim": "Gain-of-function TARDBP mutations suggest toxic gain rather than pure loss-of-function", "pmid": "24854211"},
{"claim": "Forcing nuclear retention of mutant TDP-43 didn't prevent degeneration", "pmid": "26656189"},
{"claim": "Specificity problem: splicing dysregulation should be ubiquitous if TDP-43 regulates thousands of splicing events globally", "pmid": "N/A"},
{"claim": "ASO strategies targeting RNA metabolism have failed or stalled in ALS trials", "pmid": "N/A"}
]
},
{
"title": "Autophagosome-Lysosome Fusion Defects as Primary Driver of α-Synuclein Propagation",
"description": "VPS41 and HOPS complex dysfunction impairs autophagosome-lysosome fusion, causing accumulation of α-synuclein oligomers and increased exosome release. Mechanistically plausible but causality direction remains ambiguous. Tier 3 feasibility.",
"target_gene": "VPS41, STX17, HOPS complex, TRPML1 (MCOLN1)",
"dimension_scores": {
"evidence_strength": 0.75,
"novelty": 0.68,
"feasibility": 0.58,
"therapeutic_potential": 0.65,
"mechanistic_plausibility": 0.58,
"druggability": 0.60,
"safety_profile": 0.62,
"competitive_landscape": 0.68,
"data_availability": 0.60,
"reproducibility": 0.62
},
"composite_score": 0.63,
"evidence_for": [
{"claim": "VPS41 variants associated with Parkinson's disease risk", "pmid": "28739685"},
{"claim": "Lysosomal GBA variants cause 20-fold increased PD risk", "pmid": "30664766"},
{"claim": "TRPML1 agonists (ML-SA1) enhance lysosomal function and reduce α-synuclein in mouse models", "pmid": "31109921"}
],
"evidence_against": [
{"claim": "Bidirectional causality: α-synuclein accumulation may itself impair lysosomal function", "pmid": "N/A"},
{"claim": "VPS41 GWAS evidence has modest effect sizes with unclear functional validation", "pmid": "N/A"},
{"claim": "Mechanistic link between impaired fusion and increased exosome release is asserted but not demonstrated", "pmid": "N/A"}
]
},
{
"title": "circHomer1a Restoration as Neuroprotective Strategy in Synaptic Decline",
"description": "circHomer1a reduction in AD/FTD impairs miR-1961 sponging, reducing HOMER1 translation essential for NMDA receptor signaling. Despite intriguing correlative data, mechanistic chain requires validation at each step. Tier 5 feasibility with 15+ year timeline.",
"target_gene": "circHomer1a, miR-1961, HOMER1",
"dimension_scores": {
"evidence_strength": 0.68,
"novelty": 0.80,
"feasibility": 0.40,
"therapeutic_potential": 0.55,
"mechanistic_plausibility": 0.44,
"druggability": 0.38,
"safety_profile": 0.55,
"competitive_landscape": 0.72,
"data_availability": 0.52,
"reproducibility": 0.45
},
"composite_score": 0.54,
"evidence_for": [
{"claim": "circHomer1a significantly decreased in AD prefrontal cortex", "pmid": "30012402"},
{"claim": "circHomer1a overexpression improves synaptic plasticity in hippocampal neurons", "pmid": "29670289"}
],
"evidence_against": [
{"claim": "circRNA function may be artifact of overexpression systems; many reported functions failed replication", "pmid": "N/A"},
{"claim": "HOMER1 itself unchanged—if circHomer1a→HOMER1 mechanism true, protein should also be reduced", "pmid": "N/A"},
{"claim": "AAV9 targeting to cortical neurons in adult mice is inefficient", "pmid": "N/A"},
{"claim": "miR-1961 sponging affinity and capacity not biophysically quantified", "pmid": "N/A"}
]
},
{
"title": "N-acetylation Deficiency as Novel Metabolic Vulnerabilities in Sporadic ALS",
"description": "Post-translational N-terminal acetylation defects contribute to motor neuron degeneration in sporadic ALS. However, no direct genetic link to ALS exists, and mechanistic gap from Ogden syndrome (childhood lethal) to late-onset sporadic ALS is unexplained. Tier 4 exploratory.",
"target_gene": "NAA10, NAA20, NAA80",
"dimension_scores": {
"evidence_strength": 0.62,
"novelty": 0.85,
"feasibility": 0.42,
"therapeutic_potential": 0.50,
"mechanistic_plausibility": 0.48,
"druggability": 0.35,
"safety_profile": 0.45,
"competitive_landscape": 0.78,
"data_availability": 0.48,
"reproducibility": 0.52
},
"composite_score": 0.54,
"evidence_for": [
{"claim": "NAA10 mutations cause Ogden syndrome with neurodegenerative features", "pmid": "22581936"},
{"claim": "N-terminal acetylation deficiency linked to proteostasis failure in neurodegeneration", "pmid": "29395064"},
{"claim": "Mitochondrial-localized NATs regulate mitophagy", "pmid": "30629168"},
{"claim": "Global acetylome changes observed in ALS spinal cord", "pmid": "28855058"}
],
"evidence_against": [
{"claim": "No direct genetic enrichment of NAA10/NAA20 in ALS patient cohorts", "pmid": "N/A"},
{"claim": "Mechanistic gap from catastrophic developmental syndrome to late-onset adult neurodegeneration unexplained", "pmid": "N/A"},
{"claim": "N-acetylation is pervasive; doesn't explain motor neuron specificity", "pmid": "N/A"}
]
}
],
"knowledge_edges": [
{"source_id": "SDA-2026-04-02-gap-2026-04-01-gap-006", "source_type": "analysis", "target_id": "hypothesis_1", "target_type": "hypothesis", "relation": "generates"},
{"source_id": "SDA-2026-04-02-gap-2026-04-01-gap-006", "source_type": "analysis", "target_id": "hypothesis_2", "target_type": "hypothesis", "relation": "generates"},
{"source_id": "SDA-2026-04-02-gap-2026-04-01-gap-006", "source_type": "analysis", "target_id": "hypothesis_3", "target_type": "hypothesis", "relation": "generates"},
{"source_id": "SDA-2026-04-02-gap-2026-04-01-gap-006", "source_type": "analysis", "target_id": "hypothesis_7", "target_type": "hypothesis", "relation": "generates"},
{"source_id": "hypothesis_7", "source_type": "hypothesis", "target_id": "cGAS", "target_type": "gene", "relation": "targets"},
{"source_id": "hypothesis_7", "source_type": "hypothesis", "target_id": "STING", "target_type": "gene", "relation": "targets"},
{"source_id": "hypothesis_2", "source_type": "hypothesis", "target_id": "TREM2", "target_type": "gene", "relation": "targets"},
{"source_id": "hypothesis_1", "source_type": "hypothesis", "target_id": "TARDBP", "target_type": "gene", "relation": "targets"},
{"source_id": "hypothesis_3", "source_type": "hypothesis", "target_id": "VPS41", "target_type": "gene", "relation": "targets"},
{"source_id": "hypothesis_3", "source_type": "hypothesis", "target_id": "MCOLN1", "target_type": "gene", "relation": "targets"},
{"source_id": "hypothesis_6", "source_type": "hypothesis", "target_id": "GRN", "target_type": "gene", "relation": "targets"},
{"source_id": "hypothesis_6", "source_type": "hypothesis", "target_id": "SLC16A3", "target_type": "gene", "relation": "targets"},
{"source_id": "hypothesis_5", "source_type": "hypothesis", "target_id": "NAA10", "target_type": "gene", "relation": "targets"},
{"source_id": "hypothesis_4", "source_type": "hypothesis", "target_id": "HOMER1", "target_type": "gene", "relation": "targets"},
{"source_id": "hypothesis_1", "source_type": "hypothesis", "target_id": "hypothesis_2", "target_type": "hypothesis", "relation": "shares_neuroimmune_mechanisms_with"},
{"source_id": "hypothesis_3", "source_type": "hypothesis", "target_id": "hypothesis_6", "target_type": "hypothesis", "relation": "shares_lysosomal_pathway_with"},
{"source_id": "hypothesis_5", "source_type": "hypothesis", "target_id": "hypothesis_3", "target_type": "hypothesis", "relation": "shares_proteostasis_with"},
{"source_id": "TREM2", "source_type": "gene", "target_id": "hypothesis_2", "target_type": "hypothesis", "relation": "implicated_in"},
{"source_id": "cGAS", "source_type": "gene", "target_id": "hypothesis_7", "target_type": "hypothesis", "relation": "implicated_in"},
{"source_id": "TARDBP", "source_type": "gene", "target_id": "hypothesis_1", "target_type": "hypothesis", "relation": "implicated_in"}
],
"synthesis_summary": "The Agora debate reveals a critical divergence between mechanistic confidence (dominated by TDP-43 nuclear loss at 0.82) and translational feasibility (favoring cGAS-STING at Tier 1). The Skeptic's critiques substantially revise mechanistic confidence downward for Hypotheses 1-4, identifying foundational issues including causality assumption (TDP-43), bidirectional causation (lysosome-αSyn), and epiphenomenon risk (circHomer1a). For drug development prioritization, cGAS-STING emerges as the most translationally mature pathway with Tier 1 feasibility, active STING inhibitor programs, quantifiable CSF biomarkers (IP-10, IFN-β), and a 5-8 year Phase II timeline. TREM2 microglial state transition (Hypothesis 2) and astrocyte-neuron metabolic coupling (Hypothesis 6) represent Tier 2 opportunities with moderate-high druggability but unresolved mechanistic questions regarding DAM causality and therapeutic windows. TDP-43 splicing despite highest original confidence warrants caution given sufficiency gaps and ASO trial failures; if pursued, conditional splice correction experiments in adult mice after symptom onset represent the critical falsifying experiment before committing to antisense strategies."
}